Sunday - April 12, 2026

Category Archives: Pharmaceuticals & Biotech

Graves’ Disease Treatment Market Size in the 7MM was ~ USD 4,400 million in 2023 and It is projected to grow by 2034, estimates DelveInsight

DelveInsight’s “Graves’ Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the … Continue reading →

Head and Neck Cancer Clinical Trial Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Head and Neck Cancer Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Head and Neck Cancer pipeline landscape. It covers the Head and Neck Cancer Pipeline drug profiles, including clinical and … Continue reading →

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight

DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insights 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and … Continue reading →

Vascular Dementia Clinical Trial Pipeline Accelerates as 11+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Vascular Dementia Pipeline Insights 2026” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the Vascular Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Acute On Chronic Liver Failure Clinical Trial Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Acute On Chronic Liver Failure Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 5+ pipeline drugs in the Acute On Chronic Liver Failure pipeline landscape. It covers the Acute On Chronic Liver Failure pipeline drug profiles, … Continue reading →

Active Pharmaceutical Ingredients Market to Reach $198.39 Billion by 2030

Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape – Global forecast to 2030 According to MarketsandMarkets™, the global Active Pharmaceutical Ingredients (API) Market … Continue reading →

UK Supplier Syntech Peptides Enters Growing £1 Billion Research Peptide Market with Rigorous Third-Party Verification Programme

As demand for synthetic peptide compounds in British academic and biotech laboratories reaches record levels, Syntech Peptides launches with a supply model built around independent laboratory verification, domestic cold-chain logistics, and full documentation transparency — addressing a gap that researchers … Continue reading →

K-38 Consulting Releases Healthcare CFO Services Case Study Showcasing Measurable Financial Transformation for Medical Practices

Healthcare CFO Services Raleigh, NC – April 10th, 2026 – K-38 Consulting, a leading provider of outsourced CFO and financial advisory services, announces the release of a new healthcare CFO services case study that demonstrates how strategic financial leadership can unlock … Continue reading →

Undervalued OTC Stocks Radar: ADMQ, ADIA, RDTCF, BFGFF, ROKRF Gaining Investor Attention in 2026

A new wave of undervalued OTC and small-cap stocks is beginning to surface across sectors including manufacturing, biotech, mining, and energy, as investors search for early-stage opportunities with real catalysts. Names like ADM Endeavors (OTCQB: ADMQ), Adia Nutrition Inc. (OTCQB: … Continue reading →